ZymoGenetics

ZymoGenetics, Inc was one of the oldest biotechnology/pharmaceutical companies in the USA,<ref name="New York Times-ZymoGenetics Will Become Independent of Novo Nordisk" /> based in Seattle, Washington. The company was involved in the development of therapeutic proteins. Located on Lake Union, the address of the ZymoGenetics headquarters was 1201 Eastlake Avenue East.<ref name="Homepage-ZymoGenetics, a Bristol-Myers Squibb Company">Template:Cite web</ref> It was closed in 2019 after its acquisition by Bristol Myers Squibb.<ref name="closure1">Template:Cite web</ref><ref name="closure2">Template:Cite news</ref>

The company was founded in 1981<ref name="Xconomy- Bristol-Myers Squibb to Stay in Seattle, Keep ZymoGenetics Workers">Template:Cite web</ref> by Professors Earl W. Davie and Benjamin D. Hall of the University of Washington and 1993 Nobel Laureate in Chemistry Michael Smith of the University of British Columbia.<ref name="Homepage-ZymoGenetics, a Bristol-Myers Squibb Company" /> Initially named Zymos,<ref>Template:Cite web</ref> the company was forced to change its name to ZymoGenetics under threat of trademark infringement from the similarly named semiconductor company ZyMOS.<ref>Template:Citation</ref> Soon after its founding, ZymoGenetics began working on recombinant proteins with Danish company Novo Nordisk, and was acquired by that company in 1988.<ref name="Novo Nordisk completes divestment of ZymoGenetics, Inc.">Template:Cite web</ref> It was spun off as a public company in 2000.<ref name="New York Times-ZymoGenetics Will Become Independent of Novo Nordisk">Template:Cite web</ref> Bristol-Myers Squibb acquired the company in 2010 for $885 million.<ref name="BMS forges $885M deal to buy ZymoGenetics">Template:Cite web</ref><ref>Template:Cite news</ref>

ZymoGenetics' headquarters occupied the landmark Lake Union Steam Plant building beginning in the mid-1990s.<ref>Template:Cite news</ref> This structure was built from 1914 to 1921 by Seattle City Light, the municipal electric utility.<ref name="Xconomy- What Will Happen to ZymoGenetics' Landmark Headquarters when Bristol Calls the Shots?">Template:Cite web</ref> At the time, the building was in poor condition with many broken windows; Bruce Carter, the chief executive at the time, described it as "the mother of all fixer-uppers".<ref>Template:Cite news</ref> In December 2016, ZymoGenetics announced that they would not renew the lease to the Steam Plant building, due to expire in 2019;<ref name="NotRenewingLease">Template:Cite news</ref> the Fred Hutchinson Cancer Research Center later moved into it.<ref>Template:Cite news</ref> At the time, ZymoGenetics did not plan on closing its Bothell manufacturing site;<ref name="NotRenewingLease" /> however, it was sold to Seattle Genetics in August 2017.<ref>Template:Cite news</ref> ZymoGenetics closed completely in 2019.<ref name="closure1" /><ref name="closure2" />

Corporate governance

In late 2013, the company's president, Stephen W. Zaruby, left and took up the president and chief executive officer roles at Aurinia Pharmaceuticals.<ref name="slatko2013">Template:Cite magazine</ref>

External links

• Template:Official website
• Worldwide Patent Search in European Patent Office Database for ZymoGeneticsTemplate:Dead link
• List of Patents from United States Patent and Trademark Office for ZymoGeneticsTemplate:Dead link